Averion expands European operations
28 February 2007 Boston, USA. Averion International Corp. (OTCBB:AVRO),
a clinical research organization (CRO) specializing in oncology, medical
devices, dermatology and nephrology, has opened four European-based offices.
Averion has added many professionals, including clinicians with extensive
experience conducting oncology clinical trials, to support expanded European
operations, including staffing the new facilities. “Expanding
geographically is key to our growth strategy as it supports our ability to
provide services to international clients and to capitalize on the rapid
growth that characterizes the CRO industry,” said Philip Lavin, PhD, Averion
Chief Executive Officer. “We are exceptionally pleased to recruit top
quality CRO professionals with established credentials in conducting
clinical trials, especially in oncology. We view oncology as a particularly
attractive segment for Averion in which we have proven expertise in
conducting these highly complex and often lengthy trials.” John
Shillingford, PhD, President Averion Europe GmbH, stated, “We expect this
expansion will open new opportunities for Averion as it allows us to gain
access in Central and Eastern Europe to large populations of patients. We
have already identified clinical sites within Europe with competent,
well-trained staffs to run quality trials at competitive prices.” The new
Averion offices include:
- Averion Europe GmbH, located near Frankfurt, Germany, will provide
financial, administrative and operational support for Averion’s European
operations.
- Averion Ltd., located in the United Kingdom, will oversee operations
for Averion’s clinical trials in northwestern Europe and coordinate
activities with Averion’s UK-based clients.
- Averion Clinical Research GmbH, located in Austria, will handle
responsibilities for Averion’s Central and Eastern European operations.
- Averion Sp. z.o.o., located in Poland, will provide operational
support and co-ordination of studies in Poland and the Baltic States.
To top
|
|